ARTICLE SUMMARY:
Facing its most significant recent legislative challenge—the medical device tax—the medtech industry achieved its most notable Capitol Hill success in getting the tax suspended, raising the industry’s stature in the process. Mark Leahey, head of MDMA and one of the key drivers of that effort, talks about keeping the device tax off the books, along with other important legislative and regulatory issues facing the industry.
When it comes to addressing issues affecting life science products companies in Washington, DC, the medical device industry has historically run a distant second to biopharmaceutical companies in terms of influence.
